Literature DB >> 1720593

Interferon treatment inhibits early events in vaccinia virus gene expression in infected mice.

J R Rodriguez1, D Rodriguez, M Esteban.   

Abstract

We have analyzed the role of exogenous administration of mouse interferon (IFN alpha + beta) on the replication of vaccinia virus in peritoneal cells and in the spleen of Balb/c mice. Mice were pretreated for 16 hr with IFN and then infected with a vaccinia virus recombinant expressing luciferase under an early or late virus promoter, and the enzyme activity was measured in the course of virus infection. A dose of IFN as low as 10(3) units/mouse abolished the appearance of luciferase activity in cells of the peritoneal cavity and in spleen cells. The IFN-mediated inhibition of luciferase activity was observed even when mice were infected 4 days after the administration of IFN. The IFN-treated animals were considered free of virus since neither luciferase nor viral proteins were detected in target cells several days after virus infection. Despite a severe IFN-mediated inhibition of luciferase activity, the appearance of luciferase on mRNA levels was not inhibited 6 hr after virus infection. Our finding revealed that replication of vaccinia virus in Balb/c mice is exquisitively sensitive to inhibition by IFN and that this effect occurs at early times postinfection, most likely as a result of a translational block.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720593     DOI: 10.1016/0042-6822(91)90575-v

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

Review 1.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

2.  Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Jose Luis Nájera; Carlos Oscar S Sorzano; Victoria Jiménez; Rubén González-Sanz; Mariano Esteban
Journal:  J Virol       Date:  2012-03-14       Impact factor: 5.103

3.  The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN.

Authors:  A Alcamí; J A Symons; G L Smith
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components.

Authors:  Zoe Waibler; Martina Anzaghe; Theresa Frenz; Astrid Schwantes; Christopher Pöhlmann; Holger Ludwig; Marcos Palomo-Otero; Antonio Alcamí; Gerd Sutter; Ulrich Kalinke
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

5.  Effect of cell polarization on hepatitis C virus entry.

Authors:  Christopher J Mee; Joe Grove; Helen J Harris; Ke Hu; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

6.  Role of PKR and Type I IFNs in viral control during primary and secondary infection.

Authors:  Yumi Nakayama; Erin H Plisch; Jeremy Sullivan; Chester Thomas; Charles J Czuprynski; Bryan R G Williams; M Suresh
Journal:  PLoS Pathog       Date:  2010-06-24       Impact factor: 6.823

7.  The adenovirus E3 14.7-kilodalton protein which inhibits cytolysis by tumor necrosis factor increases the virulence of vaccinia virus in a murine pneumonia model.

Authors:  J Tufariello; S Cho; M S Horwitz
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

8.  Alpha interferon augments cidofovir's antiviral and antiproliferative activities.

Authors:  Jeffrey A Johnson; J David Gangemi
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

9.  Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kappaB, and IRF3 pathways.

Authors:  Chad Myskiw; Janilyn Arsenio; Rebekah van Bruggen; Yvon Deschambault; Jingxin Cao
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

10.  CD8+ T cell-derived IFN-γ prevents infection by a second heterologous virus.

Authors:  Laura Valentine; Rashaun Potts; Mary Premenko-Lanier
Journal:  J Immunol       Date:  2012-11-07       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.